


Capturing Immune Responses with the Experts

Next Level Preclinical Vaccine
Testing Clinical Diagnostics



Who We Are



About Viroclinics-DDL

Viroclinics-DDL operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, we serve the biopharmaceutical community with our preclinical, clinical diagnostic, research & development and clinical trial logistics services.

Our extensive experience with clinical and preclinical studies, including our specialty in respiratory viruses, puts us at the forefront for supporting the development of vaccines, antibodies and antiviral compounds targeting human disease. Extensive investment in Research & Development Services allows for assay innovation and the introduction of new tools to keep analysis up to date with the increasingly demanding criteria for developing new therapeutic and prophylactic candidates.

Global Reach

Logistics activities include preparation of sampling kits, on-site sampling handling instruction, courier transport, sample tracking and tracing (e.g. guaranteeing temperature controlled supply chain and online-sample timelines), and management of sample processing labs. Viroclinics-DDL supports a smooth logistical flow of samples from all over the globe, and works together with 35 sites in North America, Central America, Latin America, Europe, Africa, Middle East and Asia-Pacific.

Quality Guaranteed

Viroclinics-DDL has adopted a high quality standard in all operations, testing procedures and reporting. The quality management system is based on NEN-EN-ISO 15189, expanded with elements of GCP and GLP, to comply with regulatory requirements and facilitate regulatory submissions.

Vaccine Development Solutions

Our vaccine development services include main virology targets such as **Influenza, Polio and RSV**.


Virovaccine Platform

We specialize in viral targets including Influenza, Polio, RSV and other targets including: Rabies, MERS, Rhino, hMPV, Dengue, Chickungunya and VZV. Our experience is based on extensive testing of VLP, live attenuated, DNA, toxoid, conjugate, inactivated and subunit vaccines.

Throughout the years Viroclinics-DDL established an impressive track record by supporting studies in all phases of vaccine development, with innovative pre-clinical models and customized clinical models. A wide range of assays are available to test vaccine safety, efficacy, immune toxicology and pharma kinetics data. The latest integrated laboratory techniques allow for high-through put analysis.

The ViroVaccine Platform Offers:

- State of the art immunological assays, including antibody and cell mediated immunity assays (ELISPOT, flow cytometry).
- High quality serology. Including haemagglutination inhibition and microneutralization assays.
- Novel research techniques including the in-house developed Virosport™ neutralization assay platform, a novel tool for antigenic characterization of viruses and serology.



Innovative assays can speed up the vaccine development process considerably, which supports swift market delivery.

Customized assays and protocol development are integrated allowing standardization and validation procedures to support routine application in a clinical trial setting:

- Flow cytometry, ELISPOT and Biospot equipment are in place to assess cell-mediated immunity, antibody dependent cell-mediated cytotoxicity, viral plaque counts, size and growth kinetics.
- Neutralization assays are equipped with multiple read outs to safeguard virus detection in clinical samples.
- Genotyping of virus isolates has been optimized to such a level that high quality gene sequences are obtained directly on patient materials with low viral load.
- High resolution viral plaque assays enable studies on inhibition of both single and multiple infection/replication cycles. With state of the art innovative research methods and technologies, Viroclinics provides high quality data to support vaccine development.

With the virovaccine platform you are assured of **faster, more efficient and innovative vaccine development**, supporting a swift market delivery.



Our Track Record

375k

Samples processed within the last 3 years

375k

Phenotypic Assays

111k

Genotypic Assays

1600

Studies

300+

Publications in peer-reviewed journals

99%

On Time Project Delivery

30

External QS Audits

International

Presence

Learn more about Viroclinics-DDL contributions to vaccine quality, safety and efficacy:

cerbaresearch.com
Cerba Research Netherlands

//cerbaresearch.com/contact-us/

Marconistraat 16, 3029 AK Rotterdam, The Netherlands

